#Japan #Tokyo #Abe Yōan-dō #Longevity Investors #Tomonari Abe

Abe Yoan-do Pharmaceutical's Landmark Achievement

Founded in 1731 in Tokyo, Abe Yoan-do Pharmaceutical has made a significant mark by being the first Japanese company to have its CEO, Tomonari Abe, selected as a speaker at the prestigious Longevity Investors Conference 2026, scheduled to take place from September 14 to September 17 in Switzerland. This conference is known for gathering the world's top investors focused on longevity and health span extensions, a rapidly growing market projected to reach approximately $8 trillion globally by 2030.

The Impact of Longevity Market

As global interest in increasing healthy life expectancy rises, the longevity market has gained considerable attention. Japan, having experienced the challenges and advantages of an aging population the earliest, is viewed as a prime example by international investors and researchers seeking to explore longevity industries. Abe Yoan-do Pharmaceutical has gained recognition on this front, being shortlisted as one of the 20 finalist teams in the global longevity science competition, XPRIZE Healthspan.

The company's commitment to quality, honed over nearly 300 years, combined with cutting-edge biotechnology research, positions it uniquely in the global longevity innovation landscape. Abe decided to participate in the upcoming conference to further highlight Japan’s pioneering efforts in this sector.

Conference Details

• - Event Name: Longevity Investors Conference 2026
• - Date: September 14 (Monday) - September 17 (Thursday), 2026
• - Location: Le Grand Bellevue Hotel, Untergschichtstrasse 17, Switzerland

Keynote Topic

Tomonari Abe's keynote will cover "The Longevity Opportunity in Asia: Building the Infrastructure for an Aging World." This topic reflects Japan's vast potential as a repository of knowledge and practical experience in addressing the challenges posed by an aging society.

Tomonari Abe's Vision

In comments regarding his upcoming role, Abe expressed, "It is an honor to present Japan's boundless potential at a conference gathering the top investors from around the world. As a leading country in the aging society, Japan possesses a treasure trove of insight and evidence in the longevity field. By merging our traditional practices that have been passed down for over 300 years with cutting-edge science, we aim to demonstrate global growth potential beyond the Japanese market."

Looking Forward

Abe Yoan-do Pharmaceutical is focused on advancing its research and development of high-purity NMN (Nicotinamide Mononucleotide) supplements and intends to collaborate with research institutions. The company is also paving the way for global expansion through partnerships with foreign investors.

About Tomonari Abe

Tomonari Abe is the 10th generation head of the Abe family and the CEO of Abe Yoan-do Pharmaceutical. He has been leading research focusing on the SIRTUIN genes associated with longevity. He has seamlessly combined Western medicine’s insights with traditional Japanese health practices, steering the enterprise towards a sustainable health society. With the company’s historical expertise and modern scientific knowledge, he is committed to elevating the longevity industry on a global scale.

Company Overview

Abe Yoan-do Pharmaceutical, established in 1731, began serving as the official doctor to the Matsudaira family (Tokugawa clan) and has evolved over approximately 300 years. The company has adapted its mission to support the health of individuals while blending ancient health wisdom with modern medical knowledge. It has made strides in NMN research and product development while also focusing on longevity, competing globally in the XPRIZE Healthspan initiative, which includes 799 teams from 58 countries vying for innovation in health span extension.

Conclusion

Abe Yoan-do Pharmaceutical exemplifies a fusion of tradition and innovation in the longevity industry. Its representation at the Longevity Investors Conference marks a pivotal moment in showcasing Japanese advancements to the global stage.